Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
333 (estimated)
Sponsor
Novo Nordisk A/S · Industry
Who this trial is looking for
This trial is looking for people who are living with overweight or obesity. Participants will take either UBT251 or a placebo, which is a treatment with no active medicine, and their group will be chosen randomly.
Are You a Good Fit for This Trial?
You may be able to join if
I am between 18 and 65 years old.
I have a BMI within the required range for my age group.
I am male or female.
I have not taken certain diabetes medications in the last 90 days.
I have passed the medical history, physical examination, and tests during screening.
You may not be able to join if
I have a known allergy to the study medicine or related products.
I have had certain diabetes medications in the last 90 days.
I have a health condition that could put my safety at risk.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. Male or female (sex at birth).
2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
* For Japanese participants: both parents of Japanese descent.
* For Chinese participants: both parents of Chinese descent.
* For non-Asian participants: b…
Inclusion Criteria:
1. Male or female (sex at birth).
2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
* For Japanese participants: both parents of Japanese descent.
* For Chinese participants: both parents of Chinese descent.
* For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
3. Age at the time of signing the informed consent:
1. For Part A: 18-55 years (both inclusive)
2. For Part B: 18-65 years (both inclusive)
3. For Part C: 18-55 years (both inclusive).
4. BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):
1. For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
2. For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
3. For Part C: 24-34.9 kg/m\^2 (both inclusive)
5. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion Criteria:
1. Known or suspected hypersensitivity to study intervention(s) or related products.
2. Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
3. Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.